For example, SFRP4 inhibits aggressive traits of hepatocellular carcinoma (HCC) cells by reducing β-catenin levels, thereby blocking the Wnt/β-catenin signaling pathway (17). Here, SFRP4 is linked to hepatocellular carcinoma.